III randomised placebo controlled trial (MIR)David S Kessler et al., The BMJ, 2018Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference armsClair Chilvers et al., The BMJ, 2001Connectivity guided theta burst transcranial magnetic stimulation versus repetitive transcranial magnetic stimulation for treatment-resistant
of a bill like this, argues, the FDA already has the power to do most of what is in the 21st Century Cures Act. Gregg Gonsalves and Mark Harrington, former members of Act Up/New York, and David A. Kessler, commissioner of the FDA from 1990 to 1997, agree that the FDA already has the tools to do what the bill's sponsors want.Again, the underlying assumption behind the 21st Century Cures Act
to prescribe a new drug being marketed by the company" in a special article in the New England Journal of Medicine. The article, whose authors included U.S. Food and Drug Administration commissioner David Aaron Kessler, also described a number of characteristics common to seeding trials:[4] * The trial is of an intervention with many competitors * Use of a trial design unlikely to achieve its stated
Recruitment Status : Completed First Posted : February 27, 2015 Last Update Posted : September 15, 2016 Sponsor: Columbia University Information provided by (Responsible Party): DavidKessler, Columbia University * Study Details * Tabular View * Results Submitted * Disclaimer * How to Read a Study RecordStudy DescriptionGo to Top of Page Study Description Study Design Arms and Interventions Outcome Investigator: David O Kessler, MD, MSc Columbia University Principal Investigator: Gerald Behr, MD Columbia University Principal Investigator: Peter S Dayan, MD, MSc Columbia University More InformationGo to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Publications: Alpern